Homology Medicines Inc logo

Homology Medicines Inc (FIXX)

Market Closed
25 Mar, 20:00
NASDAQ (NGS) NASDAQ (NGS)
NASDAQ (NGS) NASDAQ (NGS) Primary
$
0. 93
+0.01
+0.77%
$
3.02M Market Cap
- P/E Ratio
0% Div Yield
401,467 Volume
-1.98 Eps
$ 0.93
Previous Close
Day Range
0.9 0.97
Year Range
0.9 26.64
Want to track FIXX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

FIXX closed Monday higher at $0.93, an increase of 0.77% from Friday's close, completing a monthly increase of 0% or $0.93. Over the past 12 months, FIXX stock gained 0%.
FIXX is not paying dividends to its shareholders.
The last earnings report, released on Mar 11, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Homology Medicines Inc has completed 1 stock splits, with the recent split occurring on Mar 25, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

FIXX Chart

No Data

Homology Medicines Inc (FIXX) FAQ

What is the stock price today?

The current price is $0.93.

On which exchange is it traded?

Homology Medicines Inc is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is FIXX.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 3.02M.

Has Homology Medicines Inc ever had a stock split?

Homology Medicines Inc had 1 splits and the recent split was on Mar 25, 2024.

Homology Medicines Inc Profile

Biotechnology Industry
Healthcare Sector
Paul Alloway CEO
NASDAQ (NGS) Exchange
438083107 CUSIP
US Country
7 Employees
- Last Dividend
25 Mar 2024 Last Split
28 Mar 2018 IPO Date

Overview

Homology Medicines, Inc. is a pioneering genetic medicines company dedicated to transforming the lives of patients afflicted by rare genetic diseases primarily in the United States. Founded in 2015 and based in Bedford, Massachusetts, the company has positioned itself at the forefront of genetic medicine with a focus on in vivo treatments utilizing its unique human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs). These vectors are employed to deliver cutting-edge genetic therapies, including nuclease-free gene editing and gene therapy techniques, targeting a variety of genetic disorders. Homology Medicines stands out for its innovative approach to treating rare genetic diseases, leveraging the natural properties of AAVHSCs to provide potentially curative therapies.

Products and Services

  • HMI-202

    • This investigational gene therapy has completed its IND (Investigational New Drug)-enabling studies for the treatment of metachromatic leukodystrophy, a rare genetic disorder. HMI-202 showcases Homology Medicines' commitment to developing treatments for diseases with significant unmet needs, utilizing their proprietary platform to advance gene therapy solutions.

  • HMI-104

    • HMI-104 is another key product candidate that has completed IND-enabling studies. While the target disorder for HMI-104 is not specified, its development underlines Homology Medicines’ broad approach to tackling various genetic conditions through its advanced gene therapy and editing platform.

Contact Information

Address: One Patriots Park
Phone: 781 301 7277
Affiliate Program About Terms Privacy Help Contact Us
2025 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark